Vast Therapeutics
Dr. Stasko joined Vast following his role as Senior Strategic Advisor to parent company, KnowBio LLC where he was an originator of the entrepreneurial vision to develop and optimize a proprietary chemistry platform that enables the delivery of nitric oxide across multiple therapeutic areas. As President & CEO of Novan Inc., an early embodiment of this vision, he led Novan through financings totaling more than $150 million, award of government grants and contracts totaling $15 million, and a successful initial public offering in September 2016 to become a NASDAQ listed company (NOVN).
This person is not in any teams
This person is not in any offices
Vast Therapeutics
Vast is a preclinical biotechnology company focused on treating the world’s most challenging drug-resistant microbial infections that represent one of the greatest threats to global health, food security, and economic development.